China Monoclonal Antibody Therapeutics Market (2024-2029)

RESEARCH METHODOLOGY

This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global monoclonal antibody therapeutics market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the monoclonal antibody therapeutics market. The secondary sources used for this study include U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Centers for Disease Control and Prevention (CDC), The Antibody Society, World Health Organization (WHO), National Institutes of Health (NIH), European Centre for Disease Prevention and Control (ECDC), mAbs (Monoclonal Antibodies in Immunodiagnosis and Immunotherapy), Antibody Engineering & Therapeutics (AET), Therapeutic Antibodies, Antibody Technology Journal (ATJ), U.S. Department of Health and Human Services, National Institutes of Health, National Library of Medicine, National Center for Biotechnology Information, China National Medical Products Administration (NMPA), Australian Therapeutic Goods Administration (TGA), Pharmaceuticals and Medical Devices Agency (PMDA), Brazilian Health Regulatory Agency (ANVISA), International Trade Centre, Annual Reports, SEC Filings, Investor Presentations, Research Journals, Press Releases, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the global monoclonal antibody therapeutics market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side (personnel from Hospitals and Clinics, Patients, Pharmaceutical Companies, Long Term Care Centers) and supply side (C-level and D-level executives, product managers, and marketing and sales managers of key manufacturers, distributors, and channel partners, among others, from Tier 1 and Tier 2 companies engaged in offering products) across five major regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.

Approximately 70% of primary interviews were conducted with supply side representatives, while demand side participants accounted for the remaining share. The primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

The following is a breakdown of the primary respondents:

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the monoclonal antibody therapeutics market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

Bottom-up Approach

• The key players in the industry and market have been identified through extensive secondary research.
• The revenues generated from the monoclonal antibody therapeutics market business of leading players have been determined through primary and secondary research.
• All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

To know about the assumptions considered for the study, Request for Free Sample Report

Top-down Approach

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.

Data Triangulation

To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

The monoclonal antibody therapeutics market comprises drugs developed from identical immune cells that specifically target a single antigen, commonly used to treat various diseases like cancer, autoimmune disorders, and infectious diseases. These drugs are produced in large quantities and have a significant impact on the pharmaceutical industry due to their specificity and efficacy.

Stakeholders

• Pharmaceutical & Biotechnology Companies
• Life Sciences Companies
• Academic & Research Institutes
• Government Institutes
• Contract Research Organizations (CROs)
• Hospitals and Specialities Clinics
• Long-term Care Center
• Third-party Suppliers, Direct Suppliers, Distributors, and Channel Partners
• Venture Capitalists and Investors

Report Objectives

• To define, describe, and forecast the monoclonal antibody therapeutics market based on production method, sources, route of administration, therapy area, end user, and region.
• To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges).
• To analyze micromarkets for individual growth trends, prospects, and contributions to the overall monoclonal antibody therapeutics market.
• To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders.
• To forecast the market size of the segments concerning six regions, namely: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa.
• To profile the key players and analyze their market shares and core competencies
• To track and analyze competitive developments, such as acquisitions, product launches, expansions, agreements, partnerships, and collaborations.
• To benchmark players within the market using the proprietary “Competitive Leadership Mapping” framework, which analyzes market players on various parameters within the broad categories of business & product excellence strategy.  

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Geographical Analysis

• Further breakdown of the Rest of Europe monoclonal antibody therapeutics market, by country
• Further breakdown of the Rest of Asia Pacific monoclonal antibody therapeutics market, by country
• Further breakdown of the Rest of Latin America monoclonal antibody therapeutics market, by country
• Further breakdown of the Rest of Middle East monoclonal antibody therapeutics market, by country
• Further breakdown of the Rest of GCC Countries monoclonal antibody therapeutics market, by country

Company Information

• Detailed analysis and profiling of additional market players (up to five)

Segment Analysis

• Further breakdown of the other technologies and other therapeutic area into subsegments
• Cross-segment analysis